SG3 Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-13,300
Closed -$787K 1048
2021
Q3
$787K Sell
13,300
-9,200
-41% -$606K 0.02% 505
2021
Q2
$1.5M Sell
22,500
-40,000
-64% -$2.61M 0.05% 374
2021
Q1
$3.95M Buy
62,500
+12,500
+25% +$778K 0.1% 233
2020
Q4
$3.1M Buy
50,000
+40,000
+400% +$2.46M 0.06% 290
2020
Q3
$603K Sell
10,000
-60,000
-86% -$3.61M 0.02% 521
2020
Q2
$4.12M Buy
70,000
+52,500
+300% +$3.14M 0.28% 84
2020
Q1
$975K Hold
17,500
0.13% 112
2019
Q4
$1.12M Hold
17,500
0.07% 94
2019
Q3
$887K Sell
17,500
-7,500
-30% -$352K 0.08% 147
2019
Q2
$1.13M Buy
+25,000
New +$1.16M 0.13% 140

Other funds holding BMY

SG3 Management's BMY Position: Q2 2021 in Review

SG3 Management sold out of Bristol-Myers Squibb (BMY) in Q2 2021, closing a stake of 250 shares — an estimated $16.3K sold.

SG3 Management first reported a position in BMY in Q1 2018 and held it in 7 quarters. The position peaked at $2.85M in Q1 2018. 2,369 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

  • SG3 Management reported no remaining Bristol-Myers Squibb position as of Q2 2021 after selling out during the quarter.
  • SG3 Management sold 250 Bristol-Myers Squibb shares in Q2 2021, an estimated $16.3K.
  • SG3 Management first reported a position in Bristol-Myers Squibb in Q1 2018 and held it in 7 quarters.
  • SG3 Management's Bristol-Myers Squibb position peaked at $2.85M in Q1 2018.
  • 2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.